Bone Biologics Corporation
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jeffrey Frelick
- Full Time Employees
- 2
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2 Burlington Woods Drive Burlington MA United States of America 01803
- IPO Date
- Oct 13, 2021
- CIK
- 0001419554
- Website
- bonebiologics.com
- Similar Companies
- Business
- Bone Biologics Corporation (Nasdaq: BBLG), a clinical-stage medical device company, develops orthobiologic products focused on bone regeneration for spinal fusion markets using recombinant human NELL-1 protein technology. The company's lead product candidate, NB1 (NELL-1/DBM), comprises an osteopromotive recombinant protein combined with demineralized bone matrix to enable target-specific control over bone regeneration in lumbar spinal fusion procedures for skeletally mature patients with degenerative disc disease at levels L2-S1; its NELL-1 platform also supports applications in orthopedic, trauma, osteoporosis, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine surgical specialties. Founded in 2004 and headquartered in Burlington, Massachusetts, Bone Biologics holds an exclusive license from UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion, osteoporosis, and trauma; it operates primarily in the United States with an ongoing first-in-human pilot clinical trial in Australia evaluating NB1's safety and effectiveness against autograft controls in up to 30 patients undergoing transforaminal lumbar interbody fusion. Recent developments include completion of a $5.0 million public offering in June 2025 to fund clinical trials, patent extensions, and operations through Q2 2026; implementation of a 1-for-6 reverse stock split effective June 10, 2025, to maintain Nasdaq compliance; anticipation of completing enrollment in the NB1 multicenter trial by end-2025 with interim data after six-month follow-ups; and extension of NB1's shelf life to 18 months via stability studies, with plans for further extension to 24 months.
Company News
Bone Biologics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Bone Biologics Achieves 32-Month Validated Shelf Life for rhNELL-1
Bone Biologics (BBLG) to Announce Earnings on Thursday
Bone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities
Bone Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook
Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months
Bone Biologics (NASDAQ:BBLG) Shares Down 0.5% – Should You Sell?
Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook
Bone Biologics Announces Closing of $5.0 Million Public Offering
Why Is Bone Biologics Stock Surging On Friday?
Bone Biologics Announces Pricing of $5.0 Million Public Offering
Bone Biologics Files Patent Application for Bone Regeneration Technology
Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements
Bone Biologics Announces 1-for-6 Reverse Stock Split
Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds
First Two Patients Treated in Pilot Clinical Study with Bone Biologics' NB1 Bone Graft Device in Spine Fusion
Bone Biologics Announces Closing of $2.0 Million Public Offering
Bone Biologics Announces Pricing of $2.0 Million Public Offering
Bone Biologics Reports Progress With NB1 Clinical Program